OBJECTIVES: Prostate biopsy (PB) is the gold standard for the diagnosis of prostate cancer (PCa).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
However, the optimal number of biopsy cores remains debatable. We sought to compare contemporary standard (10-12 cores) vs. saturation (=18 cores) schemes on initial as well as repeat PB.
METHODS: A non-systematic review of the literature was performed from 2000 through 2013. Studies of highest evidence (randomized controlled trials, prospective non-randomized studies, and retrospective reports of high quality) comparing standard vs saturation schemes on initial and repeat PB were evaluated. Outcome measures were overall PCa detection rate, detection rate of insignificant PCa, and procedure-associated morbidity.
RESULTS: On initial PB, there is growing evidence that a saturation scheme is associated with a higher PCa detection rate compared to a standard one in men with lower PSA levels (< 10 ng/ml), larger prostates (>40 cc), or lower PSA density values (< 0.25 ng/ml/cc). However, these cut-offs are not uniform and differ among studies. Detection rates of insignificant PCa do not differ in a significant fashion between standard and saturation biopsies. On repeat PB, PCa detection rate is likewise higher with saturation protocols. Estimates of insignificant PCa vary widely due to differing definitions of insignificant disease. However, the rates of insignificant PCa appear to be comparable for the schemes in patients with only one prior negative biopsy, while saturation biopsy seems to detect more cases of insignificant PCa compared to standard biopsy in men with two or more prior negative biopsies. Very extensive sampling is associated with a high rate of acute urinary retention, whereas other severe adverse events, such as sepsis, appear not to occur more frequently with saturation schemes.
DISCUSSION: Current evidence suggests that saturation schemes are associated with a higher PCa detection rate compared to standard ones on initial PB in men with lower PSA levels or larger prostates, and on repeat PB. Since most data are derived from retrospective studies, other endpoints such as detection rate of insignificant disease - especially on repeat PB - show broad variations throughout the literature and must, thus, be interpreted with caution. Future prospective controlled trials should be conducted to compare extended templates with newer techniques, such as image-guided sampling, in order to optimize PCa diagnostic strategy.
Isbarn H, Briganti B, De Visschere PJ, Fütterer J, Ghadjar P, Giannarini G, Ost P, Ploussard G, Sooriakumaran P, Surcel C, Van Oort I, Yossepowitch O, van den Bergh R. Are you the author?
Department of Urology, Regio Clinic Wedel, Wedel, Germany. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Urological Research Institute, Vita-Salute University San Raffaele, Milan, Italy; Department of Radiology, Ghent University Hospital, Ghent, Belgium; Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Department of Radiation Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany; Urology Unit, Academic Medical Centre Hospital "Santa Maria della Misericordia", Udine, Italy; Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium; Department of Urology, Saint-Jean Languedoc Hospital, Toulouse, France; Department of Urology, CHU Saint-Louis, Assistance Publique, Hôpitaux de Paris, Université Pari, Paris, France; Surgical Intervention Trials Unit, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, U.K; Department of Molecular Medicine & Surgery, Karolinska Institutet, Stockholm, Sweden; Centre of Urological Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania; Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Department of Urology, Rabin Medical Center - Beilinson, Petach-Tikva, Israel. Sackler Faculty of Medicine, University of Tel Aviv, Tel Aviv, Israel; Department of Urology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Reference: Arch Esp Urol. 2015 Apr;68(3):296-306.